The following is a summary of the Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript:

Financial Performance:

• Inhibikase reported a net loss of $5.0 million or $0.66 per share for Q2 2024, an improvement from a loss of $5.8 million or $0.94 the previous year.

• R&D expenses decreased to $3.1 million, down from $4.5 million year over year, primarily due to reduced costs in IkT-001Pro development.

• The company secured $4 million through a direct offering and private placement, extending its cash runway into December 2024.

Business Progress:

• Successfully completed enrollment for the Phase 2 201 trial of risvodetinib in Parkinson's disease.

• Filed an IND for IkT-001Pro for pulmonary arterial hypertension, aiming to commence a Phase 2b study.

• Plans to meet with the FDA by year-end to discuss the Phase 3 trial of risvodetinib and launch a 12-month open-label extension study.

Opportunities:

• Seizing the global market for pulmonary arterial hypertension valued at $7.7 billion annually, by potentially improving the safety and tolerability profile of imatinib with IkT-001Pro.

• Advancing development of new diagnostic and clinical biomarker tools for Parkinson's disease through grant applications under review by NINDS.

Risks:

• The gradual progression of AI services, as they scale and reach general availability, implying a slower uptake and integration into markets.

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.